NYSE: QGENQiagen Nv Stock
$41.89+0.67 (+1.63%)
Updated Apr 23, 2024
QGEN Price
$41.89
Fair Value Price
N/A
Market Cap
$9.56B
52 Week Low
$35.81
52 Week High
$49.18
P/E
27.93x
P/B
2.51x
P/S
5.2x
PEG
1.11x
Dividend Yield
3.06%
Revenue
$1.97B
Earnings
$341.30M
Gross Margin
62.8%
Operating Margin
24.59%
Profit Margin
17.4%
Debt to Equity
0.61
Operating Cash Flow
$459M
Beta
0.42
Next Earnings
Apr 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QGEN Overview
Qiagen N.V. offers molecular diagnostics, applied testing, academic and pharmaceutical research. Specific offerings include nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies. It also offers secondary sample technology consumable (kits and components for purification of nucleic acids, instruments for nucleic acid purification, and accessories). Qiagen N.V was founded in 1986 and is headquartered in Venlo, the Netherlands.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QGEN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QGEN ($41.89) is trading above its intrinsic value of $21.50, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
QGEN is good value based on its earnings relative to its share price (27.93x), compared to the US market average (41.92x)
P/E vs Market Valuation
QGEN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more QGEN due diligence checks available for Premium users.
Be the first to know about important QGEN news, forecast changes, insider trades & much more!
QGEN News
Valuation
QGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.93x
Industry
38.97x
Market
41.92x
QGEN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
QGEN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
QGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.51x
Industry
4.24x
QGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QGEN price to earnings growth (PEG)
For valuing profitable companies with growth potential
QGEN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
QGEN's financial health
Profit margin
Revenue
$509.2M
Net Income
$97.7M
Profit Margin
19.2%
QGEN's Earnings (EBIT) of $483.22M... subscribe to Premium to read more.
Interest Coverage Financials
QGEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.1B
Liabilities
$2.3B
Debt to equity
0.61
QGEN's short-term assets ($2.15B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QGEN's short-term assets ($2.15B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$151.4M
Investing
-$58.5M
Financing
-$7.4M
QGEN's operating cash flow ($459.46M)... subscribe to Premium to read more.
Debt Coverage Financials
QGEN vs Diagnostic & Research Stocks
Qiagen Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.